Docetaxel Combined With Cisplatin for Metastatic Extramammary Paget Disease


    loading  Checking for direct PDF access through Ovid

Abstract

Micro-AbstractWe provided docetaxel combined with cisplatin to patients with metastatic extramammary Paget disease (EMPD). After 2 cycles of chemotherapy, 4 patients experienced partial remission and 4 stable disease; mean overall survival (OS) was 28.9 months, and mean progression-free survival was 9.9 months. Docetaxel combined with cisplatin might be a treatment option for metastatic EMPD, with good disease control rate and OS.Introduction:Metastatic extramammary Paget disease (EMPD) as a rare intraepithelial carcinoma is fatal. However, no standardized chemotherapy has been established. We provided docetaxel combined with cisplatin to EMPD patients.Patients and Methods:A total of 8 patients with metastatic EMPD were included in this study between July 2010 and July 2015 (mean age, 64.4 years); they underwent a mean of 9.4 cycles of chemotherapy. All the patients were treated with chemotherapy (docetaxel 60 mg/m2 on day 1; cisplatin 25 mg/m2 on days 1-3) as first-line treatment for > 6 cycle (at least 21 days per cycle). Data on tumor response, time to progression, overall survival, and adverse events were collected.Results:After 2 cycles of chemotherapy, 4 patients experienced partial remission and 4 stable disease. The mean overall survival was 28.9 months, and the mean progression-free survival was 9.9 months.Conclusion:Docetaxel combined with cisplatin might be a treatment option for metastatic EMPD, with high disease control rate and good overall survival.

    loading  Loading Related Articles